Attenuated Salmonella SP12 Mutants as Antigen Carriers
AssigneesMicroscience Limited, Imperial College Innovations Limited
InventorsMichael Hensel, David Holden, Jacqueline Shea
Life of this patent
Estimating the term…
Loading patent…
AssigneesMicroscience Limited, Imperial College Innovations Limited
InventorsMichael Hensel, David Holden, Jacqueline Shea
Estimating the term…
The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.
An isolated nucleic acid molecule, comprising a nucleic acid sequence comprising at least 50 nucleotides
A peptide or polypeptide comprising a peptide sequence comprising at least 20 amino acids
A polypeptide comprising the sequence
An attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell.
An attenuated gram-negative cell comprising the SPI2 gene locus, characterized by a lack of at least one SPI2 polypeptide, wherein said lack results in an attenuation/reduction of virulence compared to the wild type of said cell.
(canceled)
(canceled)
An isolated nucleic acid molecule comprising a nucleic acid of at least 100 nucleotides
(canceled)
(canceled)
Dependencies are inferred from the claim text.